Table 2. N-glycosylation site occupancies in health and liver disease conditions.
ID | Sample | OMIM entry | Clinical score | TRFE |
HPT |
IGHA1 |
IGHG2 |
||||
---|---|---|---|---|---|---|---|---|---|---|---|
mean | SEM | mean | SEM | mean | SEM | mean | SEM | ||||
001 | PMM2-CDG | 601785 | * | 86 | 2.8 | 3 | 1.0 | 82 | 2.8 | 100 | 0.0 |
002 | PMM2-CDG | 601785 | mild | 90 | 2.1 | 32 | 4.6 | 83 | 1.0 | 100 | 0.0 |
003 | PMM2-CDG | 601785 | mild/moderate | 91 | 0.7 | 24 | 3.1 | 86 | 1.0 | 100 | 0.0 |
004 | PMM2-CDG | 601785 | moderate | 91 | 1.0 | 13 | 2.2 | 87 | 0.2 | 100 | 0.0 |
005 | PMM2-CDG | 601785 | severe | 84 | 1.8 | 3 | 0.5 | 86 | 2.1 | 100 | 0.0 |
034 | AlG11-CDG | 613661 | * | 94 | 0.1 | 28 | 1.2 | 90 | 2.7 | 100 | 0.0 |
036 | AlLG1-CDG | 608540 | moderate | 82 | 2.1 | 7 | 0.4 | 91 | 0.1 | 100 | 0.0 |
037 | ALG6-CDG | 603147 | severe | 85 | 0.5 | 3 | 0.3 | 90 | 0.5 | 100 | 0.0 |
038 | MPDU1-CDG | 604041 | moderate/severe | 91 | 0.5 | 12 | 3.4 | 87 | 1.7 | 100 | 0.0 |
039 | RFT1-CDG | 612015 | severe | 72 | 1.7 | 3 | 0.7 | 91 | 1.8 | 100 | 0.0 |
007 | healthy | na | na | 93 | 0.9 | 61 | 2.5 | 84 | 1.8 | 100 | 0.0 |
008 | healthy | na | na | 94 | 0.5 | 57 | 3.2 | 86 | 1.6 | 100 | 0.0 |
009 | healthy | na | na | 93 | 1.1 | 54 | 1.8 | 85 | 1.3 | 100 | 0.0 |
010 | healthy | na | na | 95 | 0.5 | 52 | 3.1 | 84 | 1.3 | 100 | 0.0 |
011 | healthy | na | na | 95 | 0.5 | 56 | 6.5 | 86 | 4.3 | 100 | 0.0 |
012 | Steatosis | nd | <3 | 95 | 1.4 | 73 | 4.0 | 86 | 1.9 | 100 | 0.0 |
013 | Steatosis | nd | <3 | 94 | 0.5 | 71 | 5.6 | 85 | 1.0 | 100 | 0.0 |
015 | Steatosis | nd | <3 | 95 | 0.7 | 61 | 5.8 | 84 | 4.0 | 100 | 0.0 |
016 | Steatosis | nd | <3 | 95 | 0.5 | 68 | 1.9 | 87 | 1.4 | 100 | 0.0 |
014 | NASH | nd | 5 | 95 | 0.2 | 69 | 1.9 | 86 | 1.5 | 100 | 0.0 |
017 | NASH | nd | 3 | 95 | 0.8 | 59 | 5.2 | 86 | 0.9 | 100 | 0.0 |
018 | NASH | nd | 4 | 96 | 1.0 | 64 | 1.4 | 86 | 1.9 | 100 | 0.0 |
019 | NASH | nd | 5–6 | 95 | 0.7 | 69 | 4.1 | 82 | 1.4 | 100 | 0.0 |
020 | NASH | nd | 4 | 95 | 1.5 | 60 | 12.3 | 88 | 2.6 | 100 | 0.0 |
021 | NASH | nd | 4 | 94 | 0.7 | 53 | 4.4 | 88 | 3.3 | 100 | 0.0 |
022 | NASH | nd | 6 | 95 | 1.3 | 43 | 3.9 | 91 | 1.5 | 100 | 0.0 |
023 | NASH | nd | * | 94 | 0.7 | 58 | 11.5 | 90 | 2.0 | 100 | 0.0 |
The values for each glycosylation site are averaged from three technical replicates, starting with the serum sample preparation. SEM = standard error of mean. Average values derived from 5 samples from healthy serum, 4 liver steatosis samples and 8 NASH samples. OMIM = Online Mendelian Inheritance in Man, na = not applicable, nd = not determined, ID = unique sample identifier, TRFE = transferrin, HPT = haptoglobin, IGHA1 = human IgA1, IGHG2 = human IgG2, (*) = no clinical information available. The clinical score values are displayed according to Grünewald et al. or Kleiner et al. (NAFLD activity scores), respectively30,31.